BNF for Children (BNFC) 2018-2019

lSIDE-EFFECTS
▶Common or very commonHypersensitivity.oedema

lPREGNANCYNo evidence of harm inanimalstudies—
manufacturer advises caution.

lBREAST FEEDINGManufacturer advises avoid—no
information available.

lHEPATIC IMPAIRMENTManufacturer advises caution.

lMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug.
Solution for injection
▶Aranesp(Amgen Ltd)
Darbepoetin alfa 25 microgram per 1 mlAranesp
10 micrograms/ 0. 4 ml solution for injection pre-filled syringes| 4 pre-
filled disposable injectionP£ 58. 72
Aranesp 40 micrograms/ 0. 4 ml solution for injection pre-filled syringes
| 4 pre-filled disposable injectionP£ 234. 90
Aranesp 130 micrograms/ 0. 65 ml solution for injection pre-filled
syringes| 4 pre-filled disposable injectionP£ 763. 42
Aranesp 500 micrograms/ 1 ml solution for injection pre-filled syringes
Aranesp 150 micrograms/ 0. 3 ml solution for injection pre-filled
syringes| 4 pre-filled disposable injectionP£ 880. 86
▶Aranesp SureClick(Amgen Ltd)
Darbepoetin alfa 40 microgram per 1 mlAranesp SureClick
20 micrograms/ 0. 5 ml solution for injection pre-filled disposable
devices| 1 pre-filled disposable injectionP£ 29. 36
Aranesp SureClick 80 micrograms/ 0. 4 ml solution for injection pre-filled
disposable devices| 1 pre-filled disposable injectionP£ 117. 45
Aranesp SureClick 100 micrograms/ 0. 5 ml solution for injection pre-
filled disposable devices| 1 pre-filled disposable injectionP
£ 146. 81
Aranesp SureClick 300 micrograms/ 0. 6 ml solution for injection pre-
filled disposable devices| 1 pre-filled disposable injectionP
£ 440. 43
Aranesp SureClick 500 micrograms/ 1 ml solution for injection pre-filled
disposable devices| 1 pre-filled disposable injectionP£ 734. 05

eiiiiF 563

Epoetin alfa

lINDICATIONS AND DOSE BINOCRIT®PRE-FILLED SYRINGES Symptomatic anaemia associated with chronic renal failure in patients on haemodialysis ▶BY INTRAVENOUS INJECTION ▶Child (body-weight up to 10 kg):Initially 50 units/kg 3 times a week, adjusted in steps of 25 units/kg 3 times a week, dose adjusted according to response at

intervals of at least 4 weeks; maintenance 75 – 150 units/kg 3 times a week, intravenous injection to be given over 1 – 5 minutes, reduce dose by approximately^25 % if rise in haemoglobin concentration exceeds 2 g/ 100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/ 100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25 % lower than the previous dose ▶Child (body-weight 10–30 kg):Initially 50 units/kg 3 times a week, adjusted in steps of 25 units/kg 3 times a week, dose adjusted according to response at intervals of at least 4 weeks; maintenance 60 – 150 units/kg 3 times a week, intravenous injection to be given over 1 – 5 minutes, reduce dose by approximately 25 % if rise in haemoglobin concentration exceeds 2 g/ 100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/ 100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25 % lower than the previous dose ▶Child (body-weight 31 kg and above):Initially 50 units/kg 3 times a week, adjusted in steps of 25 units/kg 3 times a week, dose adjusted according to response at intervals of at least 4 weeks; maintenance 30 – 100 units/kg 3 times a week, intravenous injection to be given over 1 – 5 minutes, reduce dose by approximately 25 % if rise in haemoglobin concentration exceeds 2 g/ 100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/ 100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25 % lower than the previous dose EPREX®PRE-FILLED SYRINGES Symptomatic anaemia associated with chronic renal failure in patients on haemodialysis ▶BY INTRAVENOUS INJECTION ▶Child (body-weight up to 10 kg):Initially 50 units/kg 3 times a week, adjusted in steps of 25 units/kg 3 times a week, dose adjusted according to response at intervals of at least 4 weeks; maintenance 75 – 150 units/kg 3 times a week, intravenous injection to be given over 1 – 5 minutes, reduce dose by approximately 25 % if rise in haemoglobin concentration exceeds 2 g/ 100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/ 100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25 % lower than the previous dose ▶Child (body-weight 10–30 kg):Initially 50 units/kg 3 times a week, adjusted in steps of 25 units/kg 3 times a week, dose adjusted according to response at intervals of at least 4 weeks; maintenance 60 – 150 units/kg 3 times a week, intravenous injection to be given over 1 – 5 minutes, reduce dose by approximately 25 % if rise in haemoglobin concentration exceeds 2 g/ 100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/ 100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25 % lower than the previous dose ▶Child (body-weight 31–60 kg):Initially 50 units/kg 3 times a week, adjusted in steps of 25 units/kg 3 times a week, dose adjusted according to response at intervals of at least 4 weeks; maintenance 30 – 100 units/kg 3 times a week, intravenouscontinued→

BNFC 2018 – 2019 Hypoplastic, haemolytic, and renal anaemias 565

Blood and nutrition

9

BNF for Children (BNFC) 2018-2019

Get our desktop app

Company

Features

Documentation

Resources